Центральный несахарный диабет вследствие нейрогипофизита в периоде реконвалесценции после перенесенной COVID-19: представление клинического случая и обзор литературы

В настоящее время имеется значительное количество исследований, посвященных влиянию SARS-CoV-2 на органы эндокринной системы. Однако данные, относящиеся к патологическим изменениям гипоталамо-гипофизарной системы в контексте COVID-19, остаются ограниченными. Гипофизит – общее понятие, охватывающее разнообразные воспалительные заболевания, поражающие гипофиз и приводящие к структурным изменениям в гипоталамо-гипофизарной оси и различным уровням гормональной недостаточности в передней и/или задней доле гипофиза.

В данной работе представлен клинический случай развития центрального несахарного диабета вследствие нейрогипофизита, проявившегося через два месяца после перенесенной новой коронавирусной инфекции SARS-CoV-2 (COVID-19). Наша работа способствует расширению знаний о редком, но потенциально возможном последствии новой коронавирусной инфекции, что имеет важное значение в свете высокой распространенности инфекции COVID-19.

1. P. Caturegli, C. Newschaffer, A. Olivi, M. G. Pomper, P. C. Burger, and N. R. Rose, “Autoimmune Hypophysitis,” Endocr. Rev., vol. 26, no. 5, pp. 599–614, Aug. 2005, doi: 10.1210/er.2004-0011.

2. S. Gubbi, F. Hannah-Shmouni, C. A. Stratakis, and C. A. Koch, “Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions,” Rev. Endocr. Metab. Disord., vol. 19, no. 4, pp. 335–347, Dec. 2018, doi: 10.1007/s11154-018-9480-1.

3. J. S. Gopal-Kothandapani, V. Bagga, S. B. Wharton, D. J. Connolly, S. Sinha, and P. J. Dimitri, “Xanthogranulomatous hypophysitis: a rare and often mistaken pituitary lesion,” Endocrinol. Diabetes Metab. Case Reports, vol. 2015, no. January, Jan. 2015, doi: 10.1530/EDM-14-0089.

4. N. N. Imga, A. E. Yildirim, O. O. Baser, and D. Berker, “Clinical and hormonal characteristics of patients with different types of hypophysitis: a singlecenter experience,” Arch. Endocrinol. Metab., vol. 63, no. 1, pp. 47–52, Feb. 2019, doi: 10.20945/2359-3997000000102.

5. F. Amereller, A.-M. Küppers, K. Schilbach, J. Schopohl, and S. Störmann, “Clinical Characteristics of Primary Hypophysitis – A Single-Centre Series of 60 Cases,” Exp. Clin. Endocrinol. Diabetes, vol. 129, no. 03, pp. 234–240, Mar. 2021, doi: 10.1055/a-1163-7304.

6. S. Wang et al., “Primary lymphocytic hypophysitis: Clinical characteristics and treatment of 50 cases in a single centre in China over 18 years,” Clin. Endocrinol. (Oxf)., vol. 87, no. 2, pp. 177–184, Aug. 2017, doi: 10.1111/cen.13354.

7. K. Tanonaka and T. Marunouchi, “Angiotensinconverting enzyme 2,” Folia Pharmacol. Jpn., vol. 147, no. 2, pp. 120–121, 2016, doi: 10.1254/fpj.147.120.

8. A. C. Walls, Y. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler, “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,” Cell, vol. 181, no. 2, pp. 281–292.e6, Apr. 2020, doi: 10.1016/j.cell.2020.02.058.

9. I. Glowacka et al., “Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63,” J. Virol., vol. 84, no. 2, pp. 1198–1205, Jan. 2010, doi: 10.1128/JVI.01248-09.

10. Y. Imai et al., “Angiotensinconverting enzyme 2 protects from severe acute lung failure,” Nature, vol. 436, no. 7047, pp. 112–116, Jul. 2005, doi: 10.1038/nature03712.

11. W. J. Welch, “Angiotensin II–Dependent Superoxide,” Hypertension, vol. 52, no. 1, pp. 51–56, Jul. 2008, doi: 10.1161/HYPERTENSIONAHA.107.090472.

12. C. Marchesi, P. Paradis, and E. L. Schiffrin, “Role of the renin–angiotensin system in vascular inflammation,” Trends Pharmacol. Sci., vol. 29, no. 7, pp. 367–374, Jul. 2008, doi: 10.1016/j.tips.2008.05.003.

13. I. Hamming, W. Timens, M. Bulthuis, A. Lely, G. Navis, and H. van Goor, “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis,” J. Pathol., vol. 203, no. 2, pp. 631–637, Jun. 2004, doi: 10.1002/path.1570.

14. N. Chen et al., “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” Lancet, vol. 395, no. 10223, pp. 507–513, Feb. 2020, doi: 10.1016/S0140-6736(20)30211-7.

15. T. Han, J. Kang, G. Li, J. Ge, and J. Gu, “Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study,” Ann. Transl. Med., vol. 8, no. 17, pp. 1077–1077, Sep. 2020, doi: 10.21037/atm-20-4281.

16. Y. Ding et al., “Organ distribution of severe acute respiratory syndrome(SARS) associated coronavirus(SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways,” J. Pathol., vol. 203, no. 2, pp. 622–630, Jun. 2004, doi: 10.1002/path.1560.

17. A. M. Baig, A. Khaleeq, U. Ali, and H. Syeda, “Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms,” ACS Chem. Neurosci., vol. 11, no. 7, pp. 995–998, Apr. 2020, doi: 10.1021/acschemneuro.0c00122.

18. A. Gutenberg, J. Larsen, I. Lupi, V. Rohde, and P. Caturegli, “A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary Adenoma Preoperatively,” Am. J. Neuroradiol., vol. 30, no. 9, pp. 1766–1772, Oct. 2009, doi: 10.3174/ajnr.A1714.

19. Z. Karaca, F. Tanriverdi, K. Unluhizarci, F. Kelestimur, and H. Donmez, “Empty Sella may be the Final Outcome in Lymphocytic Hypophysitis,” Endocr. Res., vol. 34, no. 1–2, pp. 10–17, Jan. 2009, doi: 10.1080/07435800902841306.

20. S. Catford, Y. Y. Wang, and R. Wong, “Pituitary stalk lesions: systematic review and clinical guidance,” Clin. Endocrinol. (Oxf)., vol. 85, no. 4, pp. 507–521, Oct. 2016, doi: 10.1111/cen.13058.

21. M. Joshi, S. Gunawardena, A. Goenka, E. Ey, and G. Kumar, “Post COVID-19 Lymphocytic Hypophysitis: A Rare Presentation,” Child Neurol. Open, vol. 9, p. 2329048X2211030, Jan. 2022, doi: 10.1177/2329048X221103051.

22. J. Honegger et al., “Treatment of Primary Hypophysitis in Germany,” J. Clin. Endocrinol. Metab., vol. 100, no. 9, pp. 3460–3469, Sep. 2015, doi: 10.1210/jc.2015-2146.

23. B. Krishnappa et al., “Early Pulse Glucocorticoid Therapy and Improved Hormonal Outcomes in Primary Hypophysitis,” Neuroendocrinology, vol. 112, no. 2, pp. 186–195, 2022, doi: 10.1159/000516006.

24. G. A. Kaltsas et al., “Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment,” J. Clin. Endocrinol. Metab., vol. 85, no. 4, pp. 1370–1376, Apr. 2000, doi: 10.1210/jcem.85.4.6501.

25. C. Xu, A. Ricciuti, P. Caturegli, C. D. Keene, and A. Y. Kargi, “Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab,” Pituitary, vol. 18, no. 4, pp. 441–447, Aug. 2015, doi: 10.1007/s11102-014-0592-7.

26. S. Pekic et al., “Lymphocytic Hypophysitis Successfully Treated with Stereotactic Radiosurgery: Case Report and Review of the Literature,” J. Neurol. Surg. Part A Cent. Eur. Neurosurg., vol. 79, no. 01, pp. 077–085, Jan. 2018, doi: 10.1055/s-0037-1604079.

27. A. B. Sheikh, M. A. Javaid, A. A. E. Sheikh, and R. Shekhar, “Central adrenal insufficiency and diabetes insipidus as potential endocrine manifestations of covid-19 infection: A case report,” Pan Afr. Med. J., vol. 38, 2021, doi: 10.11604/pamj.2021.38.222.28243.

28. P. Nonglait, R. Naik, and N. Raizada, “Hypophysitis after COVID-19 Infection,” Indian J. Endocrinol. Metab., vol. 25, no. 3, p. 255, 2021, doi: 10.4103/ijem.ijem_329_21.

29. R. A. Misgar, A. Rasool, A. I. Wani, and M. I. Bashir, “Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection,” J. Endocrinol. Invest., vol. 44, no. 12, pp. 2855–2856, Dec. 2021, doi: 10.1007/s40618-021-01627-z.